ELI LILLY & Co is 533.2x more valuable than Aurinia Pharmaceuticals Inc. by market capitalization ($1.072 T vs $2.01 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | AUPH | LLY |
|---|---|---|
| Market cap | $2.01 B | $1.072 T |
| US-listed rank | #2095 | #10 |
| Revenue (latest FY) | $283.06M | $65.18B |
| Net income (latest FY) | $287.20M | $20.64B |
| Net margin | 101.5% | 31.7% |
| P/E (trailing FY) | 7.0 | 51.9 |
| SEC filings | 595 | 989 |
ELI LILLY & Co is 533.2x more valuable than Aurinia Pharmaceuticals Inc. by market capitalization ($1.072 T vs $2.01 B).
In their latest fiscal years, Aurinia Pharmaceuticals Inc. reported $283.06M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Aurinia Pharmaceuticals Inc. and ELI LILLY & Co, or browse the full rankings.